The Bliss Molecule: How Raphael Mechoulam Accidentally Discovered Your Body's Cannabis System

Your body has an entire biological system — one that regulates your mood, appetite, pain response, immune function, sleep, and memory — that was completely unknown to science until researchers started investigating why cannabis gets you high.

The endocannabinoid system, or ECS, is one of the most important physiological systems in the human body, and its discovery reads less like a planned scientific breakthrough and more like a chain of lucky accidents, stubborn curiosity, and a Bulgarian-Israeli chemist who couldn't understand why nobody had bothered to figure out what was actually in marijuana.

This is the story of how we found the biological system that cannabis was built to interact with — and how a molecule named after the Sanskrit word for "bliss" changed our understanding of human physiology.

The Cannabis Problem Nobody Was Solving

In the early 1960s, the scientific understanding of cannabis was embarrassingly primitive. Morphine had been isolated from opium in 1804. Cocaine had been extracted from coca leaves in 1860. But by 1963, nobody had managed to isolate and synthesize the active compound in marijuana — a plant that humans had been consuming for thousands of years.

Raphael Mechoulam, a young organic chemist at the Hebrew University of Jerusalem, found this absurd. "I was surprised to find that while the active compound of opium — morphine — had been isolated 150 years earlier, and cocaine 100 years earlier, the active compound of marijuana was not known," he later recalled.

So Mechoulam decided to figure it out himself. In 1963, he and his colleague Yechiel Gaoni successfully identified and synthesized cannabidiol — CBD. A year later, in 1964, they isolated and synthesized Delta-9-tetrahydrocannabinol — THC — confirming it as the primary psychoactive compound in cannabis.

This was groundbreaking work, but it immediately raised a deeper question: if THC produced such specific effects in the brain, there must be a receptor in the brain designed to receive it. Plants don't create molecules to interact with human biology by accident. Something in our bodies was built to respond to cannabinoids.

The hunt for that receptor would take another 24 years.

Finding the Lock

In 1988, researchers at St. Louis University made the breakthrough. Allyn Howlett and William Devane identified the first cannabinoid receptor in a rat's brain, which they designated CB1. This receptor was concentrated in areas of the brain associated with memory, coordination, movement, and cognition — which neatly explained why cannabis affects those specific functions.

The discovery of CB1 was significant for two reasons. First, it confirmed that the human brain had a specific receptor designed to interact with cannabinoid compounds. Second, the sheer density of CB1 receptors in the brain — they turned out to be among the most abundant receptor types in the entire central nervous system — suggested that whatever biological system these receptors belonged to, it was critically important.

A second cannabinoid receptor, CB2, was identified in 1993. Unlike CB1, which is concentrated in the brain and central nervous system, CB2 receptors are found primarily in the immune system and peripheral tissues. The existence of two distinct receptor types pointed toward a regulatory system with broad influence across multiple body functions.

But discovering the locks still left a key question unanswered: what were the body's own keys? If these receptors existed, the human body must produce its own compounds to activate them. Mechoulam called these hypothetical compounds "endogenous cannabinoids" — cannabinoids made by the body itself.

The Bliss Molecule

In 1992, Mechoulam's team at Hebrew University made the discovery that would give the entire system its name. Working with William Devane and Lumir Hanus, Mechoulam isolated a previously unknown lipid neurotransmitter from pig brain tissue that bound directly to the CB1 receptor.

They named it "anandamide," from the Sanskrit word "ananda," meaning bliss or supreme joy. The name was partly poetic license — anandamide doesn't produce the sustained euphoria that THC does — but it captured something important about the molecule's role. Anandamide is associated with mood regulation, pleasure response, and the sense of well-being that accompanies activities like exercise, social bonding, and eating.

Anandamide is the compound responsible for "runner's high" — that floaty, mildly euphoric feeling that kicks in during sustained exercise. For decades, scientists attributed runner's high to endorphins, but more recent research has confirmed that anandamide is the primary driver.

The discovery of anandamide was the Rosetta Stone moment. It proved that the human body produces its own cannabis-like compounds and has an entire biological system dedicated to using them.

Filling in the Map

With anandamide identified, the discoveries accelerated. In 1995, Shimon Ben-Shabat, one of Mechoulam's PhD students, discovered a second endocannabinoid: 2-arachidonoylglycerol, or 2-AG. Unlike anandamide, which binds primarily to CB1 receptors in the brain, 2-AG interacts with both CB1 and CB2 receptors and is present in significantly higher concentrations in the body.

In 2006, Mechoulam's group identified yet another endocannabinoid, arachidonoyl L-serine, expanding the known repertoire of the body's self-produced cannabinoids.

Alongside the endocannabinoids themselves, researchers identified the enzymes responsible for synthesizing and breaking them down — completing the picture of a fully functional biological system with its own production, signaling, and degradation pathways.

The endocannabinoid system, as scientists now understand it, consists of three core components: endocannabinoids (anandamide, 2-AG, and others), cannabinoid receptors (CB1 in the brain and nervous system, CB2 in the immune system and peripheral tissues), and metabolic enzymes (FAAH and MAGL, which break down endocannabinoids after use).

What the ECS Actually Does

The endocannabinoid system is a master regulator — its primary function is maintaining homeostasis, or biological balance, across virtually every major system in the body.

When your body temperature rises, the ECS helps bring it down. When inflammation flares up, the ECS sends signals to modulate the immune response. When you're stressed, anandamide production increases to help regulate your mood. When you can't sleep, the ECS plays a role in promoting rest.

The specific functions that the ECS regulates include mood and emotional processing, appetite and metabolism, pain perception, immune response and inflammation, sleep-wake cycles, memory formation and consolidation, motor control and coordination, reproductive health, bone density, and cardiovascular function.

The breadth of ECS influence explains why cannabis — which contains compounds that interact with the same receptors — produces such a wide range of effects. THC's psychoactive properties, CBD's anti-inflammatory and anxiolytic effects, and the therapeutic applications of other cannabinoids all stem from their interaction with a system that touches nearly every aspect of human physiology.

Clinical Endocannabinoid Deficiency

In 2001, neurologist Ethan Russo proposed the theory of Clinical Endocannabinoid Deficiency, which suggests that some chronic conditions — including migraines, fibromyalgia, and irritable bowel syndrome — may be caused or exacerbated by deficiencies in endocannabinoid production or function.

The theory remains an active area of research rather than an established diagnosis, but it has gained credibility as studies continue to find associations between ECS dysfunction and a range of chronic conditions. If Clinical Endocannabinoid Deficiency proves to be a valid clinical framework, it would provide a biological rationale for why some patients respond so dramatically to cannabis-based therapies.

Mechoulam's Legacy

Raphael Mechoulam, who passed away in March 2023 at the age of 92, spent six decades building the scientific foundation of cannabinoid medicine. His work — from isolating THC in 1964 to discovering anandamide in 1992 — represents one of the most consequential and underappreciated research programs in modern pharmacology.

He received Israel's top scientific honors and was widely regarded as the father of cannabinoid research, yet he never received a Nobel Prize for work that fundamentally changed our understanding of human biology. In the cannabis world, his contributions are legendary. In mainstream science, they remain underrecognized.

What makes Mechoulam's story particularly compelling is how it began: with a simple question about why nobody had figured out what was in marijuana. That curiosity — and the decades of methodical research that followed — didn't just explain how cannabis works. It revealed an entire biological system that we didn't know existed.

Why This Matters for Every Cannabis Consumer

Understanding the endocannabinoid system transforms cannabis from a recreational substance into a biological interaction. When you consume THC, you're not introducing a foreign chemical to your brain — you're activating a receptor system that your body already uses, with compounds your body already makes.

This doesn't mean cannabis use is without risk or consequence. Chronic THC exposure can downregulate CB1 receptors, leading to tolerance. Heavy use during adolescence, when the ECS is still developing, can affect brain development. And individual variation in endocannabinoid tone means that the same dose of THC can produce wildly different experiences in different people.

But it does mean that the relationship between cannabis and the human body is far more intimate and sophisticated than "plant gets you high." Sixty years after Mechoulam first asked why nobody had studied marijuana's chemistry, the answer to that question has revealed something remarkable: we were built for this interaction.

The bliss molecule was inside us all along.